These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37355357)

  • 1. Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6.
    Ardolino LC; Dear R; Armstrong AJ; Gillessen S; Joshua AM
    Eur Urol; 2023 Oct; 84(4):e94-e95. PubMed ID: 37355357
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022.
    Morris MJ; Sartor O; de Bono JS; Fizazi K; Tagawa ST
    Eur Urol; 2023 Jul; 84(1):7-8. PubMed ID: 37032186
    [No Abstract]   [Full Text] [Related]  

  • 3. [New drugs approval: Lutetium-PSMA in metastatic castration-resistant prostate cancer].
    Roulleaux Dugage M; Schlürmann F
    Bull Cancer; 2023 Jun; 110(6):600-602. PubMed ID: 37059642
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.
    Olivier T; Powell K; Prasad V
    Eur Urol; 2023 Jul; 84(1):4-6. PubMed ID: 36096857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
    N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
    Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
    Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lutetium-177-PSMA-617: A Vision of the Future.
    Chandran E; Figg WD; Madan R
    Cancer Biol Ther; 2022 Dec; 23(1):186-190. PubMed ID: 35220877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Hadaschik B; Herrmann K
    Eur Urol; 2021 Oct; 80(4):520-521. PubMed ID: 34312019
    [No Abstract]   [Full Text] [Related]  

  • 13. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177.
    Manogue CE; Chen W; Mazza A; Dang A; Lewis B; Wallis CJD; Layton J; Barata P; Sartor O; Harris KM
    Pract Radiat Oncol; 2022; 12(4):300-304. PubMed ID: 35717044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
    Keam SJ
    Mol Diagn Ther; 2022 Jul; 26(4):467-475. PubMed ID: 35553387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Prostate-Specific Antigen Changes and Clinical Outcome After
    Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
    J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.
    Sachpekidis C; Alberts I; Rominger A; Afshar-Oromieh A
    Immunotherapy; 2019 Oct; 11(15):1267-1271. PubMed ID: 31496329
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
    Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
    Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.